ROVITO, ROBERTA
ROVITO, ROBERTA
Dipartimento di Scienze della Salute
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir
2024 F. Bai, T. Beringheli, V. Vitaletti, A. Santoro, F. Molà, A. Copes, N. Gemignani, S. Pettenuzzo, R. Castoldi, B. Varisco, R. Nardo, L.B. Lundgren, R. Ligresti, M. Sala, L. Albertini, M. Augello, L. Biasioli, V. Bono, R. Rovito, T. Bini, S. Passarella, N.V. Orfeo, A.D. Monforte, G. Marchetti
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV
2024 M. Augello, V. Bono, R. Rovito, C. Tincati, S. Bianchi, L. Taramasso, A. Di Biagio, A. Callegaro, F. Maggiolo, E. Borghi, A.D. Monforte, G. Marchetti
Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection
2023 M. Augello, V. Bono, R. Rovito, C. Tincati, A. D'ARMINIO MONFORTE, G. Marchetti
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
2023 M. Augello, V. Bono, R. Rovito, C. Tincati, G. Marchetti
Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
2023 G. Marchetti, R. Rovito, V. Bono, P. Bonara, F. Bai, A.D. Monforte
Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19
2022 A. Galassi, P. Ciceri, V. Bono, L. Magagnoli, M. Sala, L. Artioli, R. Rovito, M. Hadla, V. Yellenki, A. D’Arminio Monforte, C. Tincati, M. Cozzolino, G. Marchetti
Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients
2022 R. Rovito, V. Bono, M. Augello, C. Tincati, F. Mainoldi, G. Beaudoin-Bussières, A. Tauzin, S. Bianchi, M. Hadla, V. Yellenki, A. d'Arminio Monforte, S. Casola, E. Borghi, A. Finzi, G. Marchetti
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
2022 R. Rovito, M. Augello, A. Ben-Haim, V. Bono, A. Monforte, G. Marchetti
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
2022 A. Tauzin, S.Y. Gong, G. Beaudoin-Bussières, D. Vézina, R. Gasser, L. Nault, L. Marchitto, M. Benlarbi, D. Chatterjee, M. Nayrac, A. Laumaea, J. Prévost, M. Boutin, G. Sannier, A. Nicolas, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, Y. Bo, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, R. Bazin, M. Dubé, G. De Serres, N. Brousseau, J. Richard, R. Rovito, M. Côté, C. Tremblay, G.C. Marchetti, R. Duerr, V. Martel-Laferrière, D.E. Kaufmann, A. Finzi
Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
2022 V. Bono, C. Tincati, L. Van Den Bogaart, E.S. Cannizzo, R. Rovito, M. Augello, A. De Bona, A. D'Arminio Monforte, L. Milazzo, G. Marchetti